Special Issue

Non-coding RNA as Promising Biomarker for Disease Diagnosis and Prognosis

Message from the Guest Editors

The aim of this Special Issue is to bring together international experts to provide a comprehensive overview of and recent advances in the dynamic research field of "Non-Coding RNA as a Promising Biomarker for Disease Diagnosis and Prognosis". Therefore, we invite you to participate with either an original article or a review focused on the following and other aspects:

- Non-coding RNA identification and detection;
- Molecular diagnosis of cancer and complex disease;
- Prognosis markers for infectious disease;
- Bioinformatics and experimental approaches targeting the network interactome;5. Delivery and therapeutic methods
- Delivery and therapeutic methods

Guest Editors

Prof. Dr. Shea Ping Yip

Department of Health Technology and Informatics (HTI), The Hong Kong Polytechnic University, Kowloon, Hong Kong

Dr. Chien-Ling Huang

Department of Health Technology and Informatics (HTI), The Hong Kong Polytechnic University, Kowloon, Hong Kong

Deadline for manuscript submissions

closed (31 October 2022)

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).